While reporting financial results for the first quarter on Monday, medical technology company Integra LifeSciences Holdings Corp. (IART) slashed its adjusted earnings and revenue guidance for the for the full-year 2025, while maintaining annual revenue outlook.
For the second quarter, the company expects adjusted earnings in a range of $0.40 to $0.45 per share on revenues between $390 million and $400 million, with organic revenue decline of 6.8 to 4.4 percent.
On average, ten analysts polled expect the company to report earnings of $0.57 per share on revenues of $417.04 million for the quarter. Analysts' estimates typically exclude special items.
Looking ahead to fiscal 2025, the company now projects adjusted earnings in a range of $2.19 to $2.29 per share on revenues between $1.650 billion and $1.715 billion, with organic revenue growth of 0.4 to 4.4 percent.
Previously, the company expected adjusted earnings in a range of $2.41 to $2.51 per share on revenues between $1.650 billion and $1.715 billion, with organic revenue growth of 1.0 to 5.0 percent.
The Street is looking for earnings of $2.46 per share on revenues of $1.68 billion for the year.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.